Pfizer Limited

Ramsgate Road, Sandwich, Kent, CT13 9NJ
Telephone: +44 (0)1304 616 161
Fax: +44 (0)1304 656 221

Patient Information Leaflet last updated on the eMC: 11/10/2011
PIL Caverject Dual Chamber 10 micrograms & Caverject Dual Chamber 20 micrograms

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 11/10/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to dosage and administration
Updated on 16/08/2010 and displayed until 11/10/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change of licence holder
Updated on 09/04/2009 and displayed until 16/08/2010
Reasons for adding or updating:
  • Change to side-effects
Updated on 01/08/2008 and displayed until 09/04/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 15/05/2008 and displayed until 01/08/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
Updated on 08/07/2005 and displayed until 15/05/2008
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 08/07/2005 and displayed until 08/07/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/09/2004 and displayed until 08/07/2005
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 26/09/2003 and displayed until 28/09/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 11/12/2001 and displayed until 26/09/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 01/09/2000 and displayed until 11/12/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   alprostadil